Format

Send to

Choose Destination
Curr Med Chem. 2020 Mar 20. doi: 10.2174/0929867327666200320153837. [Epub ahead of print]

Radiolabeled peptide probes for liver cancer imaging.

Author information

1
Northeastern University, College of Life and Health Sciences. China.
2
Department of Radiology, Molecular Imaging Program at Stanford (MIPS),Stanford Univeristy, Bio-X Program and Stanford Cancer Center. United States.

Abstract

Liver cancer/hepatocellular carcinoma (HCC) is a leading cause of cancer death and represents an important cause of mortality worldwide. Several biomarkers are overexpressed in liver cancer, such as the glypican 3 (GPC3) and epidermal growth factor receptor (EGFR). These biomarkers play important roles in the progression of tumors and could serve as imaging and therapeutic targets for this disease. Peptides with adequate stability, receptor binding properties, and biokinetic behavior have been intensively studied for liver cancer imaging. A great variety of them have been radiolabeled with clinically relevant radionuclides for liver cancer diagnosis, and many are promising imaging and therapeutic candidates for clinical translation. Herein, we summarize the advancement of radiolabeled peptides for the targeted imaging of liver cancer.

KEYWORDS:

EGFR; GPC3; VEGF; c-Met; liver cancer; radiolabeled peptides

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center